- |||||||||| Victoza (liraglutide) / Novo Nordisk, Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes. (Pubmed Central) - Mar 22, 2024 These real-world findings indicate that GLP-1RA-based treatment strategies could be superior to oral treatment strategies for improving TIR among patients with T2DM and that once-weekly GLP-1RA may be more effective than a once-daily GLP-1RA. Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html, identifier number ChiCTR2300073697.
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
Retrospective data, Review, Journal: Efficacy of polyethylene glycol loxenatide for type 2 diabetes mellitus patients: a systematic review and meta-analysis. (Pubmed Central) - Mar 12, 2024 And the combination of conventional hypoglycemic drugs (CHD) and PEG-Loxe could more effectively improve the levels of HbA1c, FPG, 2-h PBG, TC, TG, BMI, and BW compared with CHD in T2DM patients. Systematic Review Registration: www.inplasy.com, identifier INPLASY202350106.
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
Retrospective data, Review, Journal: Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis. (Pubmed Central) - Dec 18, 2023 Occurrence of nausea [RR 16.85 (95% CI: 3.89 to 72.92); P < 0.01; I = 10%], vomiting [RR 15.90 (95% CI: 2.99 to 84.55); P < 0.01; I = 0%], and anorexia [RR 3.85 (95% CI: 1.24 to 11.88); P = 0.02; I = 0%] was significantly higher with high-dose peg-loxenatide, as compared to placebo. Peg-loxenatide (100 mcg/week) is the most appropriate dose for clinical use as it is associated with good glycaemic efficacy with minimal gastro-intestinal side effects.
- |||||||||| metformin / Generic mfg.
Review, Journal: Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review. (Pubmed Central) - Sep 17, 2023 The 10 GLP-1RAs are exenatide (including exenatide twice daily and once weekly), liraglutide, lixisenatide, dulaglutide, PEX168, semaglutide (subcutaneous and oral semaglutide), tirzepatide and albiglutide...In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based on the NMA results, tirzepatide 15mg and semaglutide 1.0mg may be preferred.
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1695; Clinicians can rationally choose and use drugs according to the patient's conditions and needs. Compared with treatment with PEG-Loxenatide, once-weekly semaglutide represents a dominant option for treating patients with T2D in China who are not achieving glycemic control with metformin, projected to both improve clinical outcomes and reduce costs.
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
Enrollment open: Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia (clinicaltrials.gov) - Jan 19, 2022 P2/3, N=28, Recruiting, PEX-168 may regulate the expression of chemerin and omentin through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both. Not yet recruiting --> Recruiting
- |||||||||| polyethylene glycol loxenatide (PEX168) / Jiangsu Hansoh Pharma
Clinical, PK/PD data, Journal: Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. (Pubmed Central) - Sep 30, 2020 P1 A single dose of 200 μg of PEX168 was in general well tolerated in patients with renal impairment. The in vivo clearance rate of PEX168 in patients with moderate renal impairment is slower than in patients with mild renal impairment and normal renal function and dose adjustment might be required (ClinicalTrials.org #NCT02467790).
- |||||||||| Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
Trial primary completion date, Monotherapy: Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients (clinicaltrials.gov) - Jan 24, 2017 P3, N=406, Active, not recruiting, The in vivo clearance rate of PEX168 in patients with moderate renal impairment is slower than in patients with mild renal impairment and normal renal function and dose adjustment might be required (ClinicalTrials.org #NCT02467790). Trial primary completion date: Jan 2016 --> May 2016
|